Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TO-211 Phase III Clinical Study for Alternaria Allergy Skin Test Concordance
jRCT2031250355Phase 3Completed
- Sponsor
- Torii Pharmaceutical
- Start
- Oct 2025
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of TO-211 in allergy, sponsored by Torii Pharmaceutical. Primary endpoint: Primary diagnostic concordance of TO-211 vs existing Alternaria extract per acceptance criterion-1. Started Oct 2025; status: completed.
02
Drugs
TO-211
03
Conditions
allergy
Beyond the preview
Go deeper on jRCT2031250355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250355.